Form 4: Corcept Therapeutics Officer Sells Shares

Sean Maduck, President of Corcept Endocrinology, exercised stock options and subsequently sold 20,000 shares of Corcept Therapeutics common stock.

Summary

• Sean Maduck, President of Corcept Endocrinology, executed a pre-planned transaction on November 3, 2025.
• The transaction involved exercising 20,000 stock options at an exercise price of $8.27 per share.
• Immediately following the exercise, Maduck sold all 20,000 shares of common stock at a weighted average price of $73.9908 per share.
• The sale was conducted under a Rule 10b5-1 trading plan adopted on September 5, 2024.
• Following these transactions, Maduck directly holds 7,904 shares and indirectly holds 109,717 shares through various trusts and an LLC.
• Directly held shares include 265, 266, 888, and 228 shares underlying unvested restricted stock awards granted on December 2, 2024, March 3, 2025, June 2, 2025, and September 2, 2025, respectively, which vest 100% on their one-year anniversary.
• Indirect holdings include 59,717 shares via Sean and Molly Maduck Living Trust, 40,000 shares via SNM 2025 Grantor Retained Annuity Trust, and 10,000 shares via Duckhill Capital, LLC.

Sentiment

Score: 5

Explanation: A score of 5 (neutral) is assigned because while an officer sale can sometimes be viewed negatively, the transaction was pre-planned under a 10b5-1 plan, which mitigates concerns about opportunistic selling based on new, non-public information. The exercise of options also represents a realization of value from previously granted compensation.

Positives

• The exercise of stock options at a significantly lower price ($8.27) compared to the sale price ($73.9908) indicates a substantial personal gain for the officer.
• The transaction was executed under a Rule 10b5-1 plan, suggesting a pre-scheduled liquidity event rather than a reaction to recent non-public information.

Negatives

• A key officer selling 20,000 shares could be interpreted by some investors as a lack of confidence, despite the 10b5-1 plan.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This insider transaction report is specific to Corcept Therapeutics and Sean Maduck, and does not provide broader industry context or trends.

Related Party Transactions

• Sean Maduck indirectly holds shares through the Sean and Molly Maduck Living Trust, of which he is a co-trustee.
• Sean Maduck indirectly holds shares through the SNM 2025 Grantor Retained Annuity Trust, of which he is the trustee.
• Sean Maduck indirectly holds shares through Duckhill Capital, LLC, of which he is President, disclaiming beneficial ownership except to the extent of his pecuniary interest.

Stakeholder Impact

• Shareholders might interpret the sale of shares by a key officer as a potential signal, though the pre-planned nature via a 10b5-1 plan typically reduces concerns about its implications for company performance.

Next Steps

• The unvested restricted stock awards granted to Sean Maduck will vest on the one-year anniversary of their respective grant dates, provided certain requirements are satisfied.

Key Dates

Recommendation

A 'hold' recommendation is appropriate. This Form 4 primarily reports a routine, pre-planned insider transaction for liquidity purposes. It does not provide new fundamental information about Corcept Therapeutics' operations, financial health, or strategic direction that would warrant a change in investment thesis. Investors should continue to evaluate the company based on its core business performance, market position, and future prospects, rather than solely on this single insider sale.

Keywords

Corcept Therapeutics, CORT, Sean Maduck, Insider Trading, Stock Option Exercise, Share Sale, Form 4, 10b5-1 Plan, Officer Transaction